Duncan-Williams

Forest Laboratories (NYSE: FRX) and Watson Pharmaceuticals (NYSE: WPI) reached new 52-week highs of $40.52 and $66.00 per share, respectively, in Wednesday's trading session. Forest Labs saw an upgrade from Argus and Duncan-Williams upgraded its price target on the stock to $45 in the wake of...

Duncan-Williams, which raised its PT on shares of Forest Laboratories Inc. (NYSE: FRX), is providing some color on the stock. “In a recent SEC filing Forest disclosed that the Icahn parties held 7.20% of the outstanding common stock (fourth largest shareholder behind Wellington, Vanguard, and...

Duncan-Williams is out with its report today on Wright Medical Group (NASDAQ: WMGI), maintaining Buy. In a note to clients, Duncan-Williams writes, "We are maintaining our BUY rating and our twelve month price target of $18.50. This represents approximately 20 times our 2011 adjusted EPS estimate...

Duncan-Williams is out with its report today on Exactech (NASDAQ: EXAC), maintaining Buy. In a note to clients, Duncan-Williams writes, "We continue to believe that EXAC is undervalued, and we encourage investors to do due diligence on the company. Our investment thesis is focused on EXAC's...

Duncan-Williams is out with its report today on Atwood Oceanics (NYSE: ATW), reiterating Strong Buy. In a note to clients, Duncan-Williams writes, "After the close yesterday, Atwood announced a new contract for the Atwood Aurora, a jackup rig presently in the shipyard in Italy. The new contract is...

Duncan-Williams dropped its coverage of Pride International (NYSE: PDE) after the company has been taken over by ENSCO (NYSE: ESV). In a research report published today, Duncan-Williams states, "We are dropping coverage of Pride International, Inc. ENSCO (NYSE : ESV : Strong Buy rating) announced...

Duncan-Williams reiterated its Strong Buy rating on Noble Corporation (NYSE: NE). At the same time, Duncan-Williams raised its price target to $61.50 from $54, following a number of positive announcements by Noble. In a research report published today, Duncan-Williams states, "Noble released a...

Duncan-Williams reiterated its Strong Buy rating on Hercules Offshore (NASDAQ: HERO). At the same time, Duncan-Williams left its price target unchanged at $10.50, even though it lowered its 2011 earnings per share forecast. In a research report published today, Duncan-Williams states, "HERO...

Duncan-Williams reiterated its Strong Buy rating on Ensco (NYSE: ESV). At the same time, it left its price target unchanged at $68. In a research report published today, Duncan-Williams states, "ENSCO released a fleet status with numerous changes. Three new contracts and one extension in Saudi...

According to Duncan-Williams, Salix Pharmaceuticals (NASDAQ: SLXP) Buy rating is maintained. Duncan-Williams said that it is even more convinced that designing and conducting a prospective trial for Xifaxan IBS is extremely difficult and that the company will not undertake the effort. “Dr....

Duncan-Williams upgraded Noble Corporation (NYSE: NE) from Reduce to Strong Buy. The new price target was set to $54. In a research report published today, Duncan-Williams stressed it believes Noble's shares are underestimated at the moment. In the report, Duncan-Williams states, "We are upgrading...

Duncan-Williams upgraded Helmerich & Payne (NYSE: HP) from Reduce to Buy. The new price target was set to $72. In a research report published today, Duncan-Williams argued that the recent fall of 15% in value of HP's shares was unmerited, thus making its shares a worthy investment. In the...

Duncan-Williams is out with its report on Exactech (NASDAQ: EXAC), reiterating Buy. In a note to clients, Duncan-Williams writes, "We are maintaining our 2011 revenue and EPS estimates of $207 million and $1.15, respectively. This represents 9% revenue growth and 34% EPS growth compared to 2010....

Duncan-Williams is out with its report on eResearch Technology (NASDAQ: ERES), maintaining Buy. In a note to clients, Duncan-Williams writes, "ERT reported Q1:11 revenue and adjusted EPS of $41.7 million and $0.09, below our revenue estimate of $42.5 million and above our adjusted EPS estimate of...

Duncan-Williams reiterates its Reduce rating on Helmerich & Payne (NYSE: HP) in a research report published today. Helmerich & Payne reported worse than expected Q1 earnings results. Its earnings per share stood at $0.93, below consensus estimate of $0.96 and Duncan-Williams' forecast of $...